Maximum quantity allowed is 999
Please select the quantity
CAS RN: 150322-43-3 | Product Number: P2040
Prasugrel
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl Acetate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 200MG |
$118.00
|
14 | 0 | It can be shipped in about 3-4 weeks after ordering |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | P2040 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__0H__2__0FNO__3S = 373.44 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 200MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 150322-43-3 |
| Reaxys Registry Number | 9008623 |
| PubChem Substance ID | 172089108 |
| MDL Number | MFCD09954140 |
Specifications
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 120.0 to 124.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 122 °C |
GHS
Related Laws:
Transport Information:
| H.S.code* | 2934.99-000 |
Application
Studies on the Platelet Aggregation Inhibition Activity of Prasugel
References
- Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
- Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
- Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
- Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
- The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.